The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients

NCT ID: NCT00472342

Last Updated: 2007-05-11

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 182 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-03-31
• Study Completion Date: 2007-12-31

Brief Summary

Many adipokines are thought that related with metabolic disturbance such as glucose intolerance, dyslipidemia, and insulin resistance. It is reported that regular physical training could prevent the progression of diabetes from prediabetes and improve the insulin resistance. After physical training, many adipokine levels were changed due to improving insulin resistance.

In this study, we will examine the various adipokine levels such as adiponectin, RBP-4, and adrenomedullin after exercise training through exercise prescription in IFG and IGT patients.

Detailed Description

Backgrounds: Type 2 diabetes mellitus can be caused by genetic and environmental factors. Type 2 diabetes could be prevented by modifying the environmental risk factors such as physical inactivity, heavy eating, and obesity. It is reported that regular physical training could prevent the progression of diabetes from prediabetes such as impaired glucose tolerance (IGT) and impaired fasting glucose (IFG).

Prediabetes, the term of IGT and IFG, could progress to type 2 diabetes in 30~40 % within 4~5 years. Moreover, cardiovascular and cerebrovascular events are increased in prediabetic patients like as type 2 diabetic patients.

Adipose tissue is thought as a endocrine organ that secrets and regulates various hormones known as adipokines including adiponectin, resistin, leptin, visfatin, tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), and retinol-binding protein 4 (RBP 4). Recently, many adipokines are thought that related with metabolic disturbance such as glucose intolerance, dyslipidemia, and insulin resistance.

Adiponectin is known as anti-diabetic factor exerting actions on muscle fatty acid oxidation and insulin sensitivity. Plasma adiponectin levels are significantly decreased in obese, type 2 diabetes, and insulin resistant patients and correlated with insulin sensitivity. Also, adiponectin has anti-inflammatory and anti-atherogenic effects. So, adiponectin is representative insulin sensitivity marker and may be a protective factor against development of type diabetes. In previous data, there was discrepancy in effects of exercise on adiponectin levels. Some study showed exercise interventions could not have effects on adiponectin levels. However, other study suggested that physical fitness may increase adiponectin levels in obese insulin resistant adults.

RBP-4, secreted by adiocytes, has effects on reducing glucose transporter 4 (GLUT 4) in adipocytes or increasing gluconeogenesis enzyme activity such as PEPCK in the liver. Also, it is known that RBP-4 is elevated in insulin resistant patients such as type 2 diabetes and obesity. After exercise training, RBP-4 levels were decreased in subjects with improvements of insulin resistance.

Adrenomedullin (AM), originally isolated in pheochromocytoma, is recently reported as adipokine. AM is highly expressed in adipocyte of high fat diet mice or obese rat model and elevated in type 2 diabetic patients. Also, AM expression on white and brown adipose tissue was increased after adrenergic stimulation. So, it is expected that AM expression will be changed by exercise.

In this study, we will examine the various adipokine levels such as adiponectin, RBP-4, and adrenomedullin after exercise training through exercise prescription in IFG and IGT patients.

Methods

Subjects Subjects having IFG and IGT on the basis of a 75g oral glucose tolerance test (OGTT) according to American Diabetes Association criteria will be studied.

Inclusion Criteria

1. Age; 30~70

2. Subjects with IGT and IFG

3. Subjects with having possibility of exercise stress test

4. Subjects with having a strong will to this study

Exclusion Criteria

1. Age <30 or >70

2. Cr more than 1.5 mg/dL

3. AST, ALT levels more than twice as upper normal range

4. Subjects having past history of coronary artery disease

Study design

1. Study design - before and after methods

2. Visit time - baseline, after 3months, after 6months

3. 1st visit- IGT and IFG diagnosis by 75g OGTT fill up the agreement Lab sampling

4. 2nd visit - exercise stress test exercise prescription by physician follow wup lab sampling

5. 3rd visit - follow up lab sampling completing the study

6. Dietary pattern data - FFQ and 3 day dietary recall Baseline - FFQ and 3 day dietary recall 2nd visit - 3 day dietary recall 3rd visit - 3 day dietary recall After 1 year - FFQ

7. Exercise pattern data - International Physical Activity Questionnaire (IPAQ)

1st, 2nd, and 3rd visits- IPAQ 8) We will compare the parameters according to results of IPAQ (by tertile) 9) We will adjust the parameters by dietary pattern 10) Anthropometric measurements

• Height, weight, BMI, waist circumference, hip circumference 11) Exercise capacity - exercise tolerance test and Vmax O2 12) Biochemical markers
• Glucose, HbA1C, WBC, AST, ALT, GGT, total cholesterol, triglyceride, HDL cholesterol, insulin, C-peptide 13) Adipokine
• adiponectine, RBP-4, adrenomedullin 14) Insulin resistance marker
• HOMA-IR 15) Inflammatory marker
• C-reactive protein (CRP)

Conditions

Impaired Glucose Tolerance; Diabetes

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Interventions

exercise prescription

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

1. Age; 30~70

2. Subjects with IGT and IFG

3. Subjects with having possibility of exercise stress test

4. Subjects with having a strong will to this study

Exclusion Criteria

1. Age <30 or >70

2. Cr more than 1.5 mg/dL

3. AST, ALT levels more than twice as upper normal range

4. Subjects having past history of coronary artery disease

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yonsei University

OTHER

Sponsor Role: lead

Principal Investigators

Mi Young Lee, Dr

Role: PRINCIPAL_INVESTIGATOR

Department of Internal Medicine, Yonsei University Wonju College of Medicine

Choon Hee Chung, professor

Role: STUDY_CHAIR

Department of Internal Medicine, Yonsei Univerisity Wonju College of Medicine

Locations

Mi Young Lee

Wŏnju, Gangwon-do, South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Choon Hee Chung, Prefessor

Role: CONTACT

cchung@yonsei.ac.kr

82-33-741-0506

Facility Contacts

Mi Young Lee, Dr

Role: primary

domoe46@yonsei.ac.kr

82-33-741-0681

Other Identifiers

kenshin46

Identifier Type: -

Identifier Source: org_study_id